open access

Vol 25, No 5 (2020)
Original research articles
Published online: 2020-09-01
Submitted: 2020-02-08
Get Citation

Pretreatment hemoglobin level as a prognostic factor in patients with locally advanced head and neck squamous cell carcinoma

Cecília Melo-Alvim, Patrícia Miguel-Semedo, Rita Silva Paiva, Soraia Lobo-Martins, Helena Luna-Pais, Ana Lúcia Costa, Ana Rita Santos, André Florindo, Ana Luísa Vasconcelos, André N. Abrunhosa-Branquinho, Paulo Palmela, Leonor Fernandes, Dolores Lopez Presa, Luís Costa, Leonor Ribeiro
DOI: 10.1016/j.rpor.2020.07.002
·
Rep Pract Oncol Radiother 2020;25(5):768-774.

open access

Vol 25, No 5 (2020)
Original research articles
Published online: 2020-09-01
Submitted: 2020-02-08

Abstract

Aim

Evaluate pretreatment hemoglobin values as a prognostic factor in patients with locally advanced head and neck squamous cell carcinoma treated with concurrent chemoradiotherapy.

Background

Anemia is one of the most prevalent laboratory abnormalities in oncological disease. It leads to a decrease in cellular oxygen supply, altering radiosensitivity of tumor cells and compromising therapeutic outcomes.

Materials and Methods

Retrospective evaluation of patients with HNSCC treated with cCRT. Primary and secondary endpoint was to evaluate the correlation of Hb levels (≥12.5g/dL or <12.5g/dL) at the beginning of cCRT with overall survival (OS) and progression-free survival (PFS), respectively.

Results

A total of 108 patients were identified. With a median follow-up of 16.10 months median OS was 59.70 months for Hb ≥12.5g/dL vs. 14.13 months for Hb <12.5g/dL (p=0.004). PFS was 12.29 months for Hb ≥12.5g/dL and 1.68 months for Hb <12.5g/dL (p=0.016).

Conclusions

In this analysis, Hb ≥12.5g/dL correlated with significantly better OS and PFS. Further studies are needed to validate these findings.

Abstract

Aim

Evaluate pretreatment hemoglobin values as a prognostic factor in patients with locally advanced head and neck squamous cell carcinoma treated with concurrent chemoradiotherapy.

Background

Anemia is one of the most prevalent laboratory abnormalities in oncological disease. It leads to a decrease in cellular oxygen supply, altering radiosensitivity of tumor cells and compromising therapeutic outcomes.

Materials and Methods

Retrospective evaluation of patients with HNSCC treated with cCRT. Primary and secondary endpoint was to evaluate the correlation of Hb levels (≥12.5g/dL or <12.5g/dL) at the beginning of cCRT with overall survival (OS) and progression-free survival (PFS), respectively.

Results

A total of 108 patients were identified. With a median follow-up of 16.10 months median OS was 59.70 months for Hb ≥12.5g/dL vs. 14.13 months for Hb <12.5g/dL (p=0.004). PFS was 12.29 months for Hb ≥12.5g/dL and 1.68 months for Hb <12.5g/dL (p=0.016).

Conclusions

In this analysis, Hb ≥12.5g/dL correlated with significantly better OS and PFS. Further studies are needed to validate these findings.

Get Citation

Keywords

Hemoglobin; Anemia; Biomarkers; Head and neck neoplasms; Chemoradiotherapy

About this article
Title

Pretreatment hemoglobin level as a prognostic factor in patients with locally advanced head and neck squamous cell carcinoma

Journal

Reports of Practical Oncology and Radiotherapy

Issue

Vol 25, No 5 (2020)

Pages

768-774

Published online

2020-09-01

DOI

10.1016/j.rpor.2020.07.002

Bibliographic record

Rep Pract Oncol Radiother 2020;25(5):768-774.

Keywords

Hemoglobin
Anemia
Biomarkers
Head and neck neoplasms
Chemoradiotherapy

Authors

Cecília Melo-Alvim
Patrícia Miguel-Semedo
Rita Silva Paiva
Soraia Lobo-Martins
Helena Luna-Pais
Ana Lúcia Costa
Ana Rita Santos
André Florindo
Ana Luísa Vasconcelos
André N. Abrunhosa-Branquinho
Paulo Palmela
Leonor Fernandes
Dolores Lopez Presa
Luís Costa
Leonor Ribeiro

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl